Table 1.
Summary of randomized clinical studies of moxibustion for ulcerative colitis with parallel design
| First author (Year) [ref] | Sample size (M/F) Duration of disease Age (range) Setting* (author's affiliation) |
Experimental intervention | Control intervention | Response rate§ (basis of assessment) |
|---|---|---|---|---|
| Wen (2003) [16] |
69 (35/34) (A) 6 mon-14 yrs (B) 4 mon-16 yrs 23-69 yrs n.r. (TCM hospital) |
(A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 39] Indirect |
(B) Sulfasalazine (SASP, oral, 1 g × 4/d, for 3 months, n = 30) | A(89.8%, 35/39); B(66.8%, 20/30) P < 0.05 (Physician's assessment) |
| Wu (1999) [17] |
151 (n.r.) (A) 6 mon-18 yrs (B) 4 mon-16 yrs (C) 4 mon-17 yrs 25-70 yrs n.r. (TCM institute and Western hospital) |
(A) Moxa I [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 65] (B) Moxa II(same as A, n = 56) Indirect |
(C) Sulfasalazine (SASP only, oral, early: 1 g × 4/d, firmly: 0.5 g × 4/d, for 3 months, n = 30) | A(92.3%, 60/65); B(89.3%, 50/56); C (66.7%, 20/30) A, C: P < 0.01; B, C: P < 0.05 (Physician's assessment) |
| Ding (2009) [18] |
61 (32/29) (A) 3 mon-20 yrs (B) 3 mon-17 yrs 19-71 yrs n.r. (Western hospital) |
(A) Moxa [20 min, once daily for 2 months, n = 30] Indirect (ginger) |
(B) Sulphasalazine (oral, 1 g × 4/d, for 1 month, n = 31) | A(100%, 30/30); B(90.3%, 28/31) P < 0.05 (Physician's assessment, endoscopy) |
| Wang (2006) [19] |
60 (28/32) (A) 0.5-12 yrs (B) 0.6-13 yrs 27-54 yrs TCM hospital and private clinics (TCM hospital and private clinics) |
(A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 3 sessions n = 30] Indirect |
(B) Sulphasalazine (1.0 g × 4/d) and Metronidazole (0.2 g × 3/d), oral, [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 30] | A(86.7%, 26/30); B(66.7%, 20/30) P < 0.05 (Physician's assessment, endoscopy) |
| Zhou (2003) [20] | 66 (31/35) 2-8 yrs 19-50 yrs n.r. (TCM hospital) |
(A) Moxa [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 34] Indirect (ginger) |
(B) Sulfasalazine (SASP, oral, 0.5 g × 4/d), for 30 days, n = 32] plus Prednisone [(oral, 10 mg × 4/d but reduce to 10 mg/d if getting a more stable state) | A(97.1%, 33/34); B(71.9%, 23/32) P < 0.05 (Physician's assessment, endoscopy) |
Sulfasalazine: Anti-inflammatory, Metronidazole: Antibiotic, Prednisone: A synthetic anti-inflammatory glucocorticoid derived from cortisone,
SASP: salicylazosulfapyridine, ACTH: Adreno-Cortico Tropin Hormone, ACH: Adreno-Cortical Hormone
*The most of trials didn't describe the place of remision or neing treaed for active disease in the text. Alternatevely, we report the affiliation of the authors in the brackets.
§Trial divided into three or four categories, including (1) recovery, (2) marked improvement, (3) improvement, and (4) no change in terms of symptom and results of endoscopy.